8 Results for "

OCI/AML3

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "OCI/AML3" in MCE Product Catalog:

Cat. No.: HY-P1104A
CAS No.: 842166-42-1
Target:  

CXCR Akt Apoptosis

Research Areas:  

Cardiovascular Disease Cancer

FC131 TFA is a CXCR4 antagonist that inhibits AKT kinase activity in AML OCI-AML3 cells. D-ArgFC131, a derivative of FC131 TFA, inhibits the phosphorylation of downstream ERK1/2 and Akt, induces caspase-3 pathway-mediated apoptosis, and causes cell cycle arrest. FC131 TFA exerts cytotoxic effects in cancer cells such as AML cells. FC131 TFA is applicable for cancer-related research .
loading...
    loading...
Cat. No.: HY-122623A
Purity:  99.43%
Target:  

Apoptosis

Research Areas:  

Cancer

DB818 dihydrochloride is the dihydrochloride salt form of DB818 (HY-122623). DB818 dihydrochloride is an inhibitor for Homeobox A9 (HOXA9). DB818 dihydrochloride reduces the formation of HOXA9-DNA complexes, inhibits the growth and induces apoptosis in AML cell lines OCI/AML3, MV4-11, and THP-1 .
loading...
    loading...
Cat. No.: HY-P1104
CAS No.: 606968-52-9
Target:  

CXCR Akt Apoptosis

Research Areas:  

Cardiovascular Disease Cancer

FC131 is a CXCR4 antagonist that inhibits AKT kinase activity in AML OCI-AML3 cells. D-ArgFC131, a derivative of FC131, inhibits the phosphorylation of downstream ERK1/2 and Akt, induces caspase-3 pathway-mediated apoptosis, and causes cell cycle arrest. FC131 exerts cytotoxic effects in cancer cells such as AML cells. FC131 is applicable for cancer-related research .
loading...
    loading...
Cat. No.: HY-147716
CAS No.: 2415156-27-1
Target:  

CDK

Research Areas:  

Cancer

CDK8-IN-6 (compound 9) is a potent cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 13 nM. CDK8-IN-6 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 11.2, 7.5, 8.6, 20.5, 12.5-25 µM, respectively. CDK8-IN-6 has the potential for the research of AML-cancer .
loading...
    loading...
Cat. No.: HY-147717
CAS No.: 2415156-30-6
Target:  

CDK

Research Areas:  

Cancer

CDK8-IN-7 (compound 12) is a potent and selective cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 3.5 nM. CDK8-IN-7 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 5.9, 4.8, 5.4, 16.2, 12.5-25 µM, respectively. CDK8-IN-7 has the potential for the research of AML-cancer .
loading...
    loading...
Cat. No.: HY-172399
FTO-IN-14 (Compound F97) is the inhibitor for the RNA demethylase Fat mass and obesity-associated protein FTO with IC50 of 0.45 μM. FTO-IN-14 regulates the protein expression of ASB2, RARA and MYC. FTO-IN-14 exhibits antiproliferative activity in AML cancer cells (IC50 for MOLM13, NB4, HEL, OCI-AML3, MV4-11 and MONOMAC6 is 0.7-5.5 μM), induces apoptosis in NB4 cell. FTO-IN-14 exhibits antitumor activity in mouse NB4 xenograft models .
loading...
    loading...
Cat. No.: HY-175473
CAS No.: 898168-15-5
Target:  

FLT3 Apoptosis

Research Areas:  

Cancer

HI042 is a FMS-like Tyrosine Kinase 3 (FLT3) inhibitor. HI042 shows IC50 values of 0.62 μM for MOLM-13, 0.33 μM for MV4-11, and 0.89 μM for OCI-AML3 cells. HI042 selectively reduces the viability of FLT3-internal tandem duplication (FLT3-|TD) mutations-positive cell lines, induces apoptosis, disrupts cell cycle progression, and diminishes the clonogenic potential. HI042 can be used for the research of acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-160733
CAS No.: 2879330-24-0
Research Areas:  

Cancer

Menin-MLL-IN-32 (compound 51) is a Menin-MLL interaction inhibitor with an IC50 of 0.042 nM in HTRF assay. Menin-MLL-IN-32 inhibits MEIS1 mRNA expression with an IC50 of 11 nM. Menin-MLL-IN-32 shows anti-proliferative effects, with IC50 values of 8 nM, 24 nM and 1900 nM for MOLM14 cells, OCI-AML3 cells and KO-52 cells, respectively. Menin-MLL-IN-32 can be used for the study of leukemia .
loading...
    loading...